静脉窦支架术在儿童特发性颅内高压中的治疗作用:临床实践证据综述
本文系统综述了静脉窦支架术(VSS)治疗儿童难治性特发性颅内高压(IIH)的安全性与有效性。纳入6项研究共36例患儿,VSS后头痛、视乳头水肿和耳鸣均有改善,但约20%需再治疗,且缺乏标准化选择标准,需个体化决策。
要点
- VSS可改善儿童难治性IIH的头痛、视乳头水肿和耳鸣。
- 约20%患儿术后需再次支架或脑脊液分流。
- 抗血小板治疗相关出血事件需个体化管理。
核心结论
- VSS对经选择的伴静脉窦狭窄且存在跨狭窄压力梯度的儿童IIH患者安全有效。
- 其成功依赖合适的患者选择和个体化抗血小板管理。
- 需前瞻性儿童研究和标准化指南明确其治疗地位。
研究设计与样本
- 遵循PRISMA指南的系统文献综述,检索PubMed、ScienceDirect、Cochrane Library等数据库。
- 纳入1990年1月至2025年9月发表的、纽卡斯尔-渥太华量表评分≥6星的研究。
- 聚焦18岁以下、药物难治性IIH接受VSS治疗的儿童患者。
主要发现
- 共纳入6项主要研究,报告36例儿童患者(平均年龄13.32±1.25岁)。
- VSS后头痛改善87.5%,视乳头水肿改善89.5%,耳鸣改善100%。
- 66.7%的患者减少了对乙酰唑胺的需求。
- 并发症包括1例腹膜后血肿、Labbe静脉血流减少及抗血小板治疗相关轻微出血事件(鼻出血、月经过多、口腔出血导致氯吡格雷早期停用)。
- 研究间估计再治疗率约20%,部分病例需再次支架或脑脊液分流。
关键数值与推荐
- 纳入研究需纽卡斯尔-渥太华量表评分≥6星。
- VSS后头痛改善87.5%,视乳头水肿改善89.5%,耳鸣改善100%。
- 66.7%的患者减少对乙酰唑胺的需求。
- 估计再治疗率约20%。
临床怎么用
- VSS可用于经选择的伴静脉窦狭窄和跨狭窄压力梯度的儿童难治性IIH患者。
- 术前应个体化评估,缺乏标准化选择标准。
- 术后需 tailored 抗血小板管理并监测出血并发症。
局限性
- 仅纳入6项研究共36例患者,样本量小。
- 缺乏标准化儿童IIH选择标准。
- 证据不足以构成指南级别推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic intracranial hypertension (IIH) in children is a rare but vision-threatening condition characterized by elevated intracranial pressure (ICP) without an identifiable cause. While medical therapy remains the first-line approach, a subset of pediatric patients remains refractory, necessitating surgical or endovascular interventions. Venous sinus stenting (VSS) has emerged as a promising, minimally invasive alternative to cerebrospinal fluid (CSF) shunting, but its safety and efficacy in pediatric populations are not well-defined. METHODS: A systematic literature review was conducted following PRISMA guidelines, focusing on pediatric patients (< 18 years) with medically refractory IIH treated with VSS. Databases searched included PubMed, ScienceDirect, Cochrane Library, and others, including studies published from January 1990 to September 2025. Data on patient selection, procedural outcomes, complications, and antiplatelet protocols were extracted and analyzed. Only studies rated ≥ 6 stars on the Newcastle-Ottawa Scale were included. RESULTS: Six primary studies were identified, reporting outcomes in 36 pediatric patients (mean age 13.32 ± 1.25 years). VSS led to marked improvement in headache (87.5%), papilledema (89.5%), and tinnitus (100%), with reduced need for acetazolamide in 66.7%. Complications included one retroperitoneal hematoma, decreased flow in the vein of Labbe and minor hemorrhagic events related to antiplatelet therapy, including epistaxis, menorrhagia, and oral bleeding leading to early discontinuation of clopidogrel. Persistent or recurrent symptoms after stenting underscore the need for individualized, multimodal evaluation, as standardized selection criteria for pediatric IIH are still lacking. The estimated retreatment rate across studies was approximately 20%, with re-stenting or CSF shunting required in select cases. CONCLUSION: VSS appears to be a safe and effective treatment for selected pediatric IIH patients with venous sinus stenosis and demonstrable trans-stenotic gradients. However, its success relies heavily on appropriate patient selection and tailored antiplatelet management. Prospective pediatric studies and standardized guidelines are needed to clarify its optimal role in the therapeutic algorithm. Accordingly, our synthesis is intended to inform individualized decision-making in selected cases and does not constitute guideline-level recommendations.
引用
- Vacínek D, Bubeníková A, Procházka V, et al. Therapeutic role of venous sinus stenting in pediatric IIH: evidence review for clinical practice. Acta Neurochir (Wien). 2025. PMID: 41326910. doi:10.1007/s00701-025-06718-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。